12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Blinatumomab: Additional Phase I data

Data from 11 evaluable patients with diffuse large B cell lymphoma (DLBCL) in an open-label, dose-escalation Phase I trial showed that blinatumomab produced 6 objective responses, including 4 complete responses. Median duration of response has not yet been reached at a median follow-up of 7.1 months. The most...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >